三阴性乳腺癌化疗及放疗增敏作用研究进展

doi:10.12092/j.issn.1009-2501.2019.03.017

中国临床药理学与治疗学 ›› 2019, Vol. 24 ›› Issue (3): 337-342.doi: 10.12092/j.issn.1009-2501.2019.03.017

三阴性乳腺癌化疗及放疗增敏作用研究进展

李小丽^1,2,3，蔡永青⁴，周维英^1,2,3

¹重庆医科大学药学院药理学教研室，重庆 400016；²药物代谢研究重庆市重点实验室，重庆 400016；³重庆市高校生物化学与分子药理学重点实验室，重庆 400016；⁴陆军特色医学中心，重庆 400042

收稿日期:2018-11-28 修回日期:2018-12-17 出版日期:2019-03-26 发布日期:2019-04-01
通讯作者: 周维英，女，博士，教授，博士生导师，研究方向：乳腺癌侵袭转移机制及拮抗策略研究。 Tel: 023-68485161 E-mail: wyzhou0118@163.com
基金资助:
国家自然科学基金资助项目（81874100，81302797）；重庆市教育委员会科学技术研究项目（KJQN201800431）

Research progress of sensitization of chemotherapy and radiotherapy in triple-negative breast cancer

LI Xiaoli ^1,2,3，CAI Yongqing ⁴，ZHOU Weiying ^1,2,3

¹ College of Pharmacy, Chongqing Medical University, Chongqing 400016, China; ²Research Center of Pharmacodynamics Evaluation Engineering Technology of Chongqing, Chongqing 400016, China; ³ Chongqing Key Laboratory of Biochemistry and Molecular Pharmacology, Chongqing 400016, China; ⁴Army Medical Center of PLA, Chongqing 400042, China

Received:2018-11-28 Revised:2018-12-17 Online:2019-03-26 Published:2019-04-01
About author:李小丽，女，博士，副教授，研究方向：抗肿瘤药物研究。 Tel: 023-68485161 E-mail: plum181181@126.com

摘要/Abstract

摘要：

三阴性乳腺癌是指雌激素受体、孕激素受体和人表皮生长因子受体2的表达均为阴性的乳腺癌，具有预后差、复发率高、侵袭转移快和死亡率高等特点。化疗是临床治疗三阴性乳腺癌的主要手段之一，但随着治疗的进展，三阴性乳腺癌患者易产生不同程度的耐药反应，从而使治疗效果大大降低。因此，寻找有效的增敏靶点和制剂具有十分重要的治疗价值。本文将从三阴性乳腺癌放疗及化疗现状，已知的增敏靶点研究进展以及具有潜在增敏作用靶点的研究进展方面予以综述，旨在为三阴性乳腺癌化疗提供借鉴和参考。

关键词: 三阴性乳腺癌, 化疗, 放疗, 增敏

Abstract:

Triple-negative breast cancer refers to breast cancer with negative expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 (HER2). It has the characteristics of poor prognosis, high recurrence rate, rapid invasion and metastasis, and high mortality. Chemotherapy is one of the main means of clinical treatment for triple-negative breast cancer, but with the progress of treatment, triple-negative breast cancer patients are prone to produce different degrees of drug resistance, which greatly reduces the therapeutic effect. Therefore, it is of great importance to find effective targets and preparations for sensitization. This article will review the current status of triple negative breast cancer radiotherapy and chemotherapy, the research progress of known sensitization targets and potential sensitization targets, in order to provide reference for triple negative breast cancer chemotherapy.

Key words: triple-negative breast cancer, chemotherapy, radiotherapy, sensitization

中图分类号:

R737.9

李小丽，蔡永青，周维英. 三阴性乳腺癌化疗及放疗增敏作用研究进展[J]. 中国临床药理学与治疗学, 2019, 24(3): 337-342.

LI Xiaoli，CAI Yongqing，ZHOU Weiying. Research progress of sensitization of chemotherapy and radiotherapy in triple-negative breast cancer[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2019, 24(3): 337-342.

参考文献

［1］Beiki O, Hall P, Ekbom A, et al. Breast cancer incidence and case fatality among 4.7 million women in relation to social and ethnic background: a population-based cohort study［J］. Breast Cancer Res, 2012, 14(1): R5.
［2］Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence［J］. Clin Cancer Res, 2007, 13(15 Pt 1): 4429-4434.
［3］Lehmann BD, Bauer JA, Chen X, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies［J］. J Clin Invest, 2011, 121(7): 2750-2767.
［4］Abdulkarim BS, Cuartero J, Hanson J, et al. Increased risk of locoregional recurrence for women with T1-2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy［J］. J Clin Oncol, 2011, 29(21): 2852-2858.
［5］Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer［J］. J Clin Oncol, 2006, 24(36): 5652-5657.
［6］Silver DP, Richardson AL, Eklund AC, et al. Efficacy of neoadjuvant cisplatin in triple-negative breast cancer［J］. J Clin Oncol, 2010, 28(7): 1145-1153.
［7］Joensuu H, Eriksson M, Sundby Hall K, et al. Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial［J］. J Clin Oncol, 2016, 34(3): 244-250.
［8］Sparano JA, Vrdoljak E, Rixe O, et al. Randomized phase III trial of ixabepilone plus capecitabine versus capecitabine in patients with metastatic breast cancer previously treated with an anthracycline and a taxane［J］. J Clin Oncol, 2010, 28(20): 3256-3263.
［9］Twelves C, Cortes J, Vahdat L, et al. Efficacy of eribulin in women with metastatic breast cancer: a pooled analysis of two phase 3 studies［J］. Breast Cancer Res Treat, 2014, 148(3): 553-561.
［10］Doddapaneni R, Patel K, Chowdhury N, et al. Noscapine chemosensitization enhances docetaxel anticancer activity and nanocarrier uptake in triple negative breast cancer［J］. Exp Cell Res, 2016, 346(1): 65-73.
［11］Foygel K, Sekar TV, Paulmurugan R. Monitoring the antioxidant mediatechemosensitization and ARE-signaling in triple negative breast cancer therapy［J］. PLoS One, 2015, 10(11): e0141913.
［12］Robinson P, Kasembeli M, Bharadwaj U, et al. Substance P receptor signaling mediates doxorubicin-induced cardiomyocyte apoptosis and triple-negative breast cancer chemoresistance［J］. Biomed Res Int, 2016, 2016: 1959270.
［13］Thummuri D, Jeengar MK, Shrivastava S, et al. Boswellia ovalifoliolata abrogates ROS mediated NF-κB activation, causes apoptosis and chemosensitization in triple negative breast cancer cells［J］. Environ Toxicol Pharmacol, 2014, 38(1): 58-70.
［14］Her S, Cui L, Bristow RG, et al. Dual action enhancement of gold nanoparticle radiosensitization by pentamidine in triple negative breast cancer［J］. Radiat Res, 2016, 185(5): 549-562.
［15］Tseng D, Vasquez-Medano DA, Brown JM. Targeting SDF-1/CXCR4 to inhibit tumour vasculature for treatment of glioblastomas［J］. Br J Cancer, 2011, 104(12): 1805-1809.
［16］唐心宇，曹远东，孙新臣. CXCL12 受体抑制剂调控三阴性乳腺癌放射治疗的敏感性［J］. 临床肿瘤学杂志, 2017, 22(11): 973-977.
［17］Wong-Brown MW, Meldrum CJ, Carpenter JE, et al. Prevalence of BRCA1 and BRCA2 germline mutations in patients with triple-negative breast cancer［J］. Breast Cancer Res Treat, 2015, 150(1): 71-80.
［18］Comen EA, Robson M. Inhibition of poly(ADP)-ribose polymerase as a therapeutic strategy for breast cancer［J］. Oncology, 2010, 24(1): 55-62.
［19］Gelmon KA, Hirte HW, Robidoux A, et al. Can we define tumors that will respond to PARP inhibitors-A phase II correlative study of olaparib in advanced serous ovarian cancer and triple-negative breast cancer［J］. J Clin Oncol, 2010, 28(15): 3002.
［20］Jang NY, Kim DH, Cho BJ, et al. Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer［J］. BMC Cancer, 2015, 15: 89.
［21］Ouyang M, Li Y, Ye S, et al. MicroRNA profiling implies new markers of chemoresistance of triple-negative breast cancer［J］. PLoS One, 2014, 9(5): e96228.
［22］Li HY, Liang JL, Kuo YL, et al. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer［J］. Breast Cancer Res, 2017, 19(1): 133.
［23］Das S. Identification and targeting of microRNAs modulating acquired chemotherapy resistance in Triple negative breast cancer (TNBC): A better strategy to combat chemoresistance［J］. Med Hypotheses, 2016, 96: 5-8.
［24］Bousquet G, El Bouchtaoui M, Sophie T, et al. Targeting autophagic cancer stem-cells to reverse chemoresistance in human triple negative breast cancer［J］. Oncotarget, 2017, 8(21): 35205-35221.
［25］Moreira MP, da Conceicao Braga L, Cassali GD, et al. STAT3 as a promising chemoresistance biomarker associated with the CD44+/high/CD24-/low/ALDH+ BCSCs-like subset of the triple-negativebreast cancer (TNBC) cell line［J］. Exp Cell Res, 2018, 363(2): 283-290.
［26］Soleymani Abyaneh H, Gupta N, Radziwon-Balicka A, et al. STAT3 but not HIF-1α is important in mediating hypoxia-induced chemoresistance in MDA-MB-231, a triple negative breast cancer cell line［J］. Cancers (Basel), 2017, 9(10):137.
［27］Singel SM, Cornelius C, Zaganjor E, et al. KIF14 promotes AKT phosphorylation and contributes tochemoresistance in triple-negative breast cancer［J］. Neoplasia, 2014, 16(3): 247-56, 256.e2.
［28］周维英. 肿瘤研究的新焦点--外体［J］. 第三军医大学学报, 2016, 38(1): 1-7.
［29］Ciravolo V, Huber V, Ghedini GC, et al. Potential role of HER2-overexpressing exosomes in countering trastuzumab-based therapy［J］. J Cell Physiol, 2012, 227(2): 658-667.
［30］Al-Nedawi K, Meehan B, Micallef J, et al. Intercellular transfer of the oncogenic receptor EGFRv III by microvesicles derived from tumour cells［J］. Nat Cell Biol, 2008, 10(5): 619-624.
［31］Safaei R, Larson BJ, Cheng TC, et al. Abnormal lysosomal trafficking and enhanced exosomal export of cisplatin in drug-resistant human ovarian carcinoma cells［J］. Mol Cancer Ther, 2005, 4(10): 1595-1604.
［32］Xu W, Luo T, Li P, et al. RGD-conjugated gold nanorods induce radiosensitization in melanoma cancer cells by downregulating αvβ3 expressionI［J］. Int J Nanomedicine, 2012, 7: 915-924.
［33］Hall H, Hubbell JA. Matrix-bound sixth Ig-like domain of cell adhesion molecule L1 acts as an angiogenic factor by ligating αvβ3-integrin and activating VEGF-R2［J］. Microvasc Res, 2004, 68(3): 169-178.
［34］Chu QD, Panu L, Holm NT, et al. High chemokine receptor CXCR4 level in triple negative breast cancer specimens predicts poor clinical outcome［J］. J Surg Res, 2010, 159(2): 689-695.
［35］Li P, Zhang Q, Torossian A, et al. Simultaneous inhibition of EGFR and PI3K enhances radiosensitivity in human breast cancer［J］. Int J Radiat Oncol Bio Phys, 2012, 83(3): e391-397.
［36］Rahimi M, George J, Tang C. EGFR variant mediated invasion by enhanced CXCR4 expression through transcriptional and post-translational mechanisms［J］. Int J Cancer, 2010, 126(8): 1850-1860.
［37］Speers C, Zhao SG, Chandler B, et al. Androgen receptor as a mediator and biomarker of radioresistance in triple-negative breast cancer［J］. NPJ Breast Cancer, 2017, 3:29.

[1]	王如玥, 谢飞, 王欣, 李红玉. 脾多肽注射液对化疗后KM小鼠骨髓抑制和免疫力低下的治疗作用[J]. 中国临床药理学与治疗学, 2023, 28(9): 1000-1007.
[2]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[3]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[4]	李爽, 韩淑贞, 戴瑜婷, 修明慧, 杜籼芹, 和建政, 蔺兴遥. 基于多种化疗肠损伤发生机制的中医药防治进展[J]. 中国临床药理学与治疗学, 2023, 28(5): 583-593.
[5]	吴蓉蓉, 陈智强, 贾翼菲, 陈宏绮, 王盼盼, 燕茹. 靶向抑制肠道菌β-葡萄糖醛酸苷酶在肿瘤预防和治疗中的应用[J]. 中国临床药理学与治疗学, 2021, 26(8): 964-974.
[6]	鲁琼, 朱海宏, 戚听听, 李国华, 滕欣琪, 屈强, 屈健. OCTN2基因多态性影响结直肠癌奥沙利铂化疗敏感性[J]. 中国临床药理学与治疗学, 2021, 26(4): 401-407.
[7]	赵全凤, 符佩姝, 谷文睿, 郑丹, 吕宗杰, 杨洋. GnRHa用于化疗后生育力保护的循证医学研究进展[J]. 中国临床药理学与治疗学, 2021, 26(12): 1449-1454.
[8]	田亚丽, 奉林, 赵万, 谷敏, 沈涵菁, 柴晓艳. BRCA1基因多态性与转移性食管鳞癌顺铂联合卡培他滨化疗敏感性及预后关系[J]. 中国临床药理学与治疗学, 2021, 26(10): 1118-1126.
[9]	张德志, 刘猛, 朱少功, 刘桂举, 季节. XELOX方案对比卡培他滨单药方案在老年结直肠癌患者术后辅助化疗中的疗效及安全性探讨[J]. 中国临床药理学与治疗学, 2020, 25(8): 926-936.
[10]	赵文超, 邱艳芳, 谭嵘. 肿瘤治疗中靶向DNA损伤反应[J]. 中国临床药理学与治疗学, 2020, 25(8): 943-952.
[11]	唐慕菲, 沈芸竹, 张保国. CYP2D6基因多态性对托烷司琼预防化疗所致恶心呕吐效果的影响[J]. 中国临床药理学与治疗学, 2020, 25(7): 817-822.
[12]	赵妙惠，周佳妮，漆勇. 桑黄多糖调控PI3K/AKT/mTOR通路抑制肝癌腹水荷瘤小鼠及对化疗的减毒增效作用[J]. 中国临床药理学与治疗学, 2020, 25(4): 401-407.
[13]	王爱娟，过怿赟，汪志求. 阿帕替尼联合卡培他滨三线治疗晚期三阴性乳腺癌的临床观察[J]. 中国临床药理学与治疗学, 2020, 25(4): 433-439.
[14]	赵全铭，杨洋. 晚期三阴性乳腺癌的药物治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(4): 475-480.
[15]	潘露萍，石武杰，沈志鹏. 依托泊苷联合卡铂用于复发性髓母细胞瘤患儿的疗效与安全性[J]. 中国临床药理学与治疗学, 2020, 25(2): 189-195.

三阴性乳腺癌化疗及放疗增敏作用研究进展

Research progress of sensitization of chemotherapy and radiotherapy in triple-negative breast cancer

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价